The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.
about
Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza VaccinesInfluenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza VaccinesPolarizing T and B Cell Responses by APC-Targeted Subunit VaccinesTowards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensingInfluenza virus vaccines: lessons from the 2009 H1N1 pandemicInfluenza vaccination accelerates recovery of ferrets from lymphopeniaPotent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse modelInfluenza and Memory T Cells: How to Awake the ForceInfluenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and SafetyA history of influenzaEffect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccineAn interspecific Nicotiana hybrid as a useful and cost-effective platform for production of animal vaccinesIncidence of H1N1 2009 virus infection through the analysis of paired plasma specimens among blood donors, FrancePrevalence of 2009 pandemic influenza A (H1N1) virus antibodies, Tampa Bay Florida--November-December, 2009Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccinationImmunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patientsUniversal influenza virus vaccines and therapeutic antibodies.Epitope specific T-cell responses against influenza A in a healthy population.Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.The dynamics of infection and the persistence of immunity to A(H1N1)pdm09 virus in Israel.Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production.Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rateModel answers or trivial pursuits? The role of mathematical models in influenza pandemic preparedness planningLong-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adultsIncreased transmissibility explains the third wave of infection by the 2009 H1N1 pandemic virus in England.DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.Prevalence of antibodies to European porcine influenza viruses in humans living in high pig density areas of Germany.Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.Avian influenza: a pandemic waiting in the wings?Simplifying influenza vaccination during pandemics: sublingual priming and intramuscular boosting of immune responses with heterologous whole inactivated influenza vaccine.Influenza vaccination in immunocompromised patients: efficacy and safety.Scientific barriers to developing vaccines against avian influenza viruses.Seasonal influenza vaccination and technologies.Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies.Characterization of pandemic influenza immune memory signature after vaccination or infection.Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines.Determinants of influenza transmission in South East Asia: insights from a household cohort study in VietnamHemagglutination inhibiting antibodies and protection against seasonal and pandemic influenza infectionDistinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination.
P2860
Q26744622-91961625-2771-48BA-8718-1B751F74EF09Q26783844-F1F4C71E-1D83-43E7-91CD-CDE18ABA08F4Q26800145-26141EC9-731D-4329-81DE-8436B210E83DQ27003874-77E9D123-8F64-485F-8957-DAC709563222Q27027029-7C0B87A6-3DE3-44A5-9148-2DB552110562Q27321447-7229EE60-8EE5-40B6-8410-D047183FF5F0Q27330580-C4CA446E-508F-4771-8405-584959A6CE2BQ28070255-11BBDF5B-490D-40BF-9EFE-2738EE4393FBQ28079486-2AA21BD7-BE8F-4314-B5AF-2A7C7D9020B2Q28189170-011773E6-1ECC-407D-BB8C-B2A9E933611DQ28728791-44FAB4E9-A4D4-499F-9C4A-03B3F3D27751Q28730453-E45B287D-D849-4258-B902-C6991EA05D26Q28730980-C5EFCF4C-9C94-4B7E-A12C-8E986CFC0537Q28741061-F0E14C5E-475F-4B8C-8334-85FF07B7D3DDQ28742312-90DEFE7E-24C2-4134-91A3-205CBE676060Q28743021-12366FFA-C920-4604-85CC-77DC9B20E592Q30151337-EFF6B954-AAC8-4985-B07E-EFA529DCE556Q30202358-C0EC3EC0-C553-430C-8D9A-B23C8B8A3E2BQ30205252-C8AF699A-D4F4-4508-8F49-A1AD0BFC118EQ30223536-1AB00E2E-D298-4FBE-B8A0-9E7AC7DA1848Q30227434-885F86BD-73EC-4823-9BAB-0A83CB493C12Q30229527-EFCB6AB7-4065-4169-A97A-CE5D2AE03D77Q30230076-4B7CBD23-7B3F-4B7A-86CA-C0B1E28E9FD0Q30352137-897E00E5-1D8F-4E9F-993A-6EA61527D65DQ30352299-D55DE789-52D2-4410-BB91-88A71451AF0CQ30352934-15679DD9-6949-463E-8584-45F265A71E18Q30353414-658C1B16-336C-4062-8868-4A40ED924183Q30357144-808CFBE6-8A3A-458D-B043-DEB0339C389CQ30357794-DB6C5BEE-D869-441A-868C-1D4F1A83EB7AQ30358537-6B1499B2-674E-465E-9780-CE8C4A5B17B9Q30358640-18585DBF-2D30-42B7-BB59-84D990C736BFQ30360468-0DD2A688-5C51-446A-ABF8-E63DCD5E524EQ30360897-D35B90B1-3992-455C-900B-0B087BF6F9D0Q30362618-EE43F7E2-6DE4-40AA-BF0C-DBD3457C671CQ30363416-02D3369D-C725-4A5D-82A5-C5B3DAABEE9DQ30363581-4EF92E8E-0FA8-4FBA-AE5A-660E21CDCB8EQ30365391-7C6EC3D9-29F5-4EA4-A9AB-EC35F018607AQ30365932-080A5D26-26D7-4FED-AA9B-30D8157DF5A8Q30366832-D62AB9A6-D0E7-4634-8868-A467AF78132DQ30368005-81FEDFCD-F3B7-4DE9-8D86-E8A580FC436B
P2860
The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.
description
1972 nî lūn-bûn
@nan
1972年の論文
@ja
1972年論文
@yue
1972年論文
@zh-hant
1972年論文
@zh-hk
1972年論文
@zh-mo
1972年論文
@zh-tw
1972年论文
@wuu
1972年论文
@zh
1972年论文
@zh-cn
name
The role of serum haemagglutin ...... th influenza A2 and B viruses.
@en
The role of serum haemagglutin ...... th influenza A2 and B viruses.
@nl
type
label
The role of serum haemagglutin ...... th influenza A2 and B viruses.
@en
The role of serum haemagglutin ...... th influenza A2 and B viruses.
@nl
prefLabel
The role of serum haemagglutin ...... th influenza A2 and B viruses.
@en
The role of serum haemagglutin ...... th influenza A2 and B viruses.
@nl
P2093
P2860
P1476
The role of serum haemagglutin ...... th influenza A2 and B viruses.
@en
P2093
P2860
P304
P356
10.1017/S0022172400022610
P577
1972-12-01T00:00:00Z